• Overview
  • Eligibility
  • More info
  • Locations

CART-19 Cells For Patients With Minimal Residual Disease (MRD) Positive CD19+ Acute Lymphoblastic Leukemia (NCT03027739)

CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of relapse as defined by MRD+ status.
  • Biological: CART-19
    CART-19 cells treated
    Ages eligible for Study
    1 Years to 60 Years
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    No
    Inclusion Criteria:
    • Signed written informed consent
    • Aged between 1-60 years
    • Patients with MRD positive CD19+ ALL
    • Cardiac: Left ventricular ejection fraction ≥ 50%
    • Adequate renal and hepatic function
    • Performance status: Karnofsky ≥ 70%
    Exclusion Criteria:
    • Pregnant or lactating females.
    • Any co-morbidity precluding the administration of CART-19 cells.

    1 locations

    China (1)
    • Fujian Medical University Union Hospital
      recruiting
      Fuzhou, Fujian, China, 350001
    Status:
    recruiting
    Type:
    Interventional
    Phase:
    Ⅱ, Ⅲ
    Start:
    31 October, 2016
    Updated:
    18 January, 2017
    Participants:
    20
    Apply
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!